201 ELLIOTT AVENUE WEST, SEATTLE, WA
Financial Results, Press Release
Earnings Release
FDA Approves YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
Unaudited Pro Forma Condensed Consolidated Financial Statements
Announce asset purchase and license agreement for clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
Announces Pricing of $22 Million Registered Direct Offering
FY 2025
Q3
Q2
Q1
Amended Annual Report
FY 2024
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement
Free Writing Prospectus
Prospectus filed pursuant to Rule 305(b)(2)